Neurocrine Biosciences traded at $97.91 this Tuesday July 5th, decreasing $1.34 or 1.35 percent since the previous trading session. Looking back, over the last four weeks, Neurocrine Biosciences lost 3.98 percent. Over the last 12 months, its price rose by 0.47 percent. Looking ahead, we forecast Neurocrine Biosciences to be priced at 96.56 by the end of this quarter and at 88.92 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
98.07
Daily Change
-1.19%
Yearly
0.64%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 153.20 -0.60 -0.39% 32.38%
Acadia Pharmaceuticals 15.22 0.85 5.92% -36.93%
Acorda Therapeutics 0.48 -0.001 -0.15% -89.54%
Agios Pharmaceuticals 24.78 1.42 6.08% -56.72%
ALKERMES 31.03 0.50 1.64% 21.40%
Alnylam Pharmaceuticals 149.00 0.75 0.50% -14.56%
Amgen 245.31 -0.24 -0.10% 0.68%
Aptinyx Inc 0.54 -0.01 -2.18% -81.06%
Biogen 211.89 1.26 0.60% -38.56%
BioMarin Pharmaceutical 85.19 0.21 0.25% 0.73%
Cytokinetics 43.33 2.33 5.68% 121.86%
Dynavax Technologies 13.54 0.58 4.48% 42.53%
Enanta Pharmaceuticals 52.20 2.57 5.18% 19.40%
Exelixis 22.05 0.48 2.23% 19.90%
Gilead Sciences 62.10 -0.26 -0.42% -9.22%
Halozyme Therapeutics 45.93 1.45 3.26% -0.56%
Intercept Pharmaceuticals 14.87 0.74 5.24% -21.90%
Incyte Corp 78.64 0.97 1.25% -5.64%
Ionis Pharmaceuticals 37.80 -0.26 -0.68% -3.89%
Intra Cellular Therapies 55.45 0.28 0.51% 31.71%
Neurocrine Biosciences 98.07 -1.18 -1.19% 0.64%
Nektar Therapeutics 3.85 0.10 2.53% -77.26%
Pfizer 51.28 -1.03 -1.97% 30.52%
Prothena 29.18 1.29 4.63% -47.62%
Ultragenyx Pharmaceutical 64.16 1.51 2.41% -29.82%
Regeneron Pharmaceuticals 591.30 -4.10 -0.69% 1.55%
Repligen 165.86 -0.66 -0.40% -18.72%
Rigel Pharmaceuticals 1.26 0.01 0.80% -71.49%
Sarepta Therapeutics 74.14 -1.57 -2.07% 1.24%
Teva Pharmaceutical Industries Ltd 2,746.00 0 0% -13.97%
Vertex Pharmaceuticals 287.94 0.62 0.22% 43.93%
Xoma 21.07 0.23 1.10% -38.05%

Indexes Price Day Year
USND 11279 151.63 1.36% -23.08%
US2000 1725 -2.41 -0.14% -24.14%

Neurocrine Biosciences
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing, and delivering treatments for people with neurological, endocrine and psychiatric disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis, uterine fibroids, and clinical programs in multiple therapeutic areas. The Company's product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has two dosing options (40 milligram (mg) and 80 mg capsules). ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease. ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women. ORIAHNN (elagolix, estradiol, and norethindrone acetate; elagolix) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.